Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
about
Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral AntibodyHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHIV vaccine trial preparedness among Spanish-speaking Latinos in the US.Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesAnalysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineCofactors that may influence vaccine responses.Receptor binding domain based HIV vaccines.Humoral responses to independent vaccinations are correlated in healthy boosted adultsInfluenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic featuresSafety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh.Genomics meets HIV-1Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection.A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialPilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administrationRepresentation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts.Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.Immunoglobulin GM and KM genes and measles vaccine-induced humoral immunity.Determinants of HIV-1 broadly neutralizing antibody induction.The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses.Enhancing diversity in the public health research workforce: the research and mentorship program for future HIV vaccine scientists.Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults
P2860
Q27666197-ED3C7525-7C62-40DB-9EB8-AFCC4630112FQ29307502-72F3B927-69A6-43CD-A778-BAC136F64A13Q30230248-58598A51-71A6-462E-B06E-617FBBB6DDCEQ33911935-2A6DA5D3-F248-44DE-897B-C105E590996FQ34057942-259AD8DA-6237-406D-B135-2AB04804EB9FQ34157802-CE30411F-E20C-475B-A11A-839463C99C7CQ34297930-88CCBE18-641A-487E-90F9-7344083F4EDBQ35033862-9E6BB2B9-2CB9-499D-AB1E-BC390334F1CAQ35068548-BFCA6AEE-EEC5-4E3B-B6E3-7C6863807FA6Q35146181-F98E4FCF-3F1B-4EB1-9BB4-A9D3B5884D51Q35630515-829E2B14-FE2F-4CC1-8E59-8FBE2ADB411BQ36094640-FF2EABD8-51B4-4A6B-A8FC-5490910BE2FBQ36412269-CF9AFB16-1FE3-41C8-8712-458478CF8BB7Q36607295-CF7C3943-74C0-4111-8A05-3AD767C3862DQ36694846-FB3E9C0D-F6FD-46EA-A4CD-EF8EC9566559Q36748019-908C0378-CAA6-4D66-8BC1-249D1B5AA21BQ37409508-F701521D-5165-46DF-BFF0-EC07AB818433Q37693231-16F12C8D-9BF4-4F87-BAD0-EB0D0210E177Q38186768-8EE2A18F-8B30-466A-B07D-E5B52FB78605Q38919962-6CFEB957-667F-4DBD-A464-A6ACF1D04F8BQ40476608-F93F5321-4F5C-4A80-BA8A-3EE032F927F9Q50539849-3629DFA4-4F62-4259-B84F-245032BB6751Q51801819-639C7179-E44E-40A7-AE56-7057ED755C69Q53565788-95F82EEF-2635-41C4-A174-6E49BD4623B3Q56974226-ED5F219F-4498-4558-ABF7-BF9B592D1CECQ58436528-EFFB93D7-4D80-4449-8552-75FC17B5C86A
P2860
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Demographic factors that influ ...... ombinant HIV-1 gp120 vaccines.
@en
type
label
Demographic factors that influ ...... ombinant HIV-1 gp120 vaccines.
@en
prefLabel
Demographic factors that influ ...... ombinant HIV-1 gp120 vaccines.
@en
P2093
P50
P356
P1476
Demographic factors that influ ...... ombinant HIV-1 gp120 vaccines.
@en
P2093
Barbara Metch
HIV Vaccine Trials Network
Kent J Weinhold
Steve Self
P304
P356
10.1086/425518
P407
P577
2004-10-28T00:00:00Z